Revealing Engagement Patterns Among Endometrial Cancer Patients
NCT05998798 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-08-21
Summary
The study intends to investigate the personal experiences of endometrial cancer patients who take part in a separate clinical study including a specific medication intervention. The major focus will be on closely following individuals' rates of trial completion and withdrawal.
The data collected from this study will help improve future outcomes for all endometrial cancer patients as well as those in under-represented demographic groups.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-30
- Primary Completion
- 2025-09-30
- Completion
- 2026-09-30
Countries
- United States
Study Locations
More Related Trials
-
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
NCT01307631 ·Status: COMPLETED ·Phase: PHASE2
-
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
NCT05364905 ·Status: COMPLETED
-
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT04291612 ·Status: RECRUITING
-
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
NCT01455493 ·Status: COMPLETED ·Phase: PHASE2
-
Endometrial Cancer Biomarker Changes Following Exposure to Metformin
NCT02042495 ·Status: WITHDRAWN ·Phase: PHASE2
-
Appraising Medical Trial Experiences of Ovarian Cancer Patients
NCT05801796 ·Status: NOT_YET_RECRUITING
-
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT05691010 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
NCT03042897 ·Status: WITHDRAWN ·Phase: NA
-
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
NCT06240598 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT03660826 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
NCT05112991 ·Status: RECRUITING ·Phase: PHASE2
-
Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer
NCT02082470 ·Status: COMPLETED ·Phase: NA
-
Endometrial Cancer Recurrence in Patients Taking Metformin
NCT05192850 ·Status: WITHDRAWN
-
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT02728258 ·Status: COMPLETED ·Phase: PHASE2
-
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
NCT02059265 ·Status: TERMINATED ·Phase: PHASE2
-
Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas
NCT06213571 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
PErsonalized TReatment for Endometrial Carcinoma
NCT05655260 ·Status: RECRUITING ·Phase: NA
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112 ·Status: RECRUITING ·Phase: PHASE3
-
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
NCT00003821 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
NCT05320757 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT00027690 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT01295489 ·Status: COMPLETED
-
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01225887 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
NCT00522301 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT05797831 ·Status: RECRUITING ·Phase: PHASE2/PHASE3